Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs CNS deal with BioFocus

Astellas Pharma is to focus on central nervous system (CNS) disorders with the help of BioFocus

Astellas Pharma has signed a collaboration agreement with BioFocus focused on discovering novel targets in the field of central nervous system disorders.  

Under the agreement, BioFocus will utilise its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.  

Dr Chris Newton, managing director of BioFocus, said: "We are delighted to support Astellas Pharma in its research. Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology."

12th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics